Mike Kratky
Stock Analyst at Leerink Partners
(2.78)
# 1,963
Out of 5,067 analysts
35
Total ratings
50%
Success rate
32.31%
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Maintains: Outperform | $127 → $128 | $98.04 | +30.56% | 2 | Oct 1, 2025 | |
| INSP Inspire Medical Systems | Maintains: Market Perform | $116 → $97 | $117.29 | -17.30% | 7 | Aug 15, 2025 | |
| MDT Medtronic | Initiates: Outperform | $110 | $103.20 | +6.59% | 1 | Jun 16, 2025 | |
| BBNX Beta Bionics | Initiates: Outperform | $28 | $31.40 | -10.83% | 1 | Feb 24, 2025 | |
| TXG 10x Genomics | Downgrades: Market Perform | $25 → $12 | $20.13 | -40.39% | 2 | Feb 13, 2025 | |
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $62.21 | +39.85% | 2 | Oct 25, 2024 | |
| PEN Penumbra | Initiates: Outperform | $263 | $298.11 | -11.78% | 1 | Sep 3, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $21.47 | +109.59% | 2 | Apr 25, 2024 | |
| NPCE NeuroPace | Initiates: Outperform | $22 | $16.26 | +35.30% | 1 | Jan 30, 2024 | |
| PODD Insulet | Initiates: Outperform | $184 | $337.53 | -45.49% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $38.88 | +8.02% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $342 | $568.48 | -39.84% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $84.71 | -11.46% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $37 | $30.01 | +23.29% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $28.39 | -68.30% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $325 → $50 | $16.31 | +206.56% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $1.57 | +2,766.24% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $587.92 | -46.42% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $65.59 | -52.74% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $23.32 | -39.97% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $32.03 | +24.88% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $392 → $384 | $29.12 | +1,218.68% | 1 | Aug 11, 2022 |
Boston Scientific
Oct 1, 2025
Maintains: Outperform
Price Target: $127 → $128
Current: $98.04
Upside: +30.56%
Inspire Medical Systems
Aug 15, 2025
Maintains: Market Perform
Price Target: $116 → $97
Current: $117.29
Upside: -17.30%
Medtronic
Jun 16, 2025
Initiates: Outperform
Price Target: $110
Current: $103.20
Upside: +6.59%
Beta Bionics
Feb 24, 2025
Initiates: Outperform
Price Target: $28
Current: $31.40
Upside: -10.83%
10x Genomics
Feb 13, 2025
Downgrades: Market Perform
Price Target: $25 → $12
Current: $20.13
Upside: -40.39%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $62.21
Upside: +39.85%
Penumbra
Sep 3, 2024
Initiates: Outperform
Price Target: $263
Current: $298.11
Upside: -11.78%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $21.47
Upside: +109.59%
NeuroPace
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $16.26
Upside: +35.30%
Insulet
Oct 16, 2023
Initiates: Outperform
Price Target: $184
Current: $337.53
Upside: -45.49%
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $38.88
Upside: +8.02%
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $568.48
Upside: -39.84%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $84.71
Upside: -11.46%
Oct 16, 2023
Initiates: Outperform
Price Target: $37
Current: $30.01
Upside: +23.29%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $28.39
Upside: -68.30%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $325 → $50
Current: $16.31
Upside: +206.56%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $1.57
Upside: +2,766.24%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $587.92
Upside: -46.42%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $65.59
Upside: -52.74%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $23.32
Upside: -39.97%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $32.03
Upside: +24.88%
Aug 11, 2022
Maintains: Outperform
Price Target: $392 → $384
Current: $29.12
Upside: +1,218.68%